Jasper Therapeutics, Inc. (NASDAQ:JSPRW)
| Market Cap | 50.38K-96.5% |
| Revenue (ttm) | 0 |
| Net Income | -31.77M+65.1% |
| EPS | -1.59+73.5% |
| Shares Out | 16.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,925 |
| Open | 0.08 |
| Previous Close | 0.00 |
| Day's Range | 0.00 - 0.08 |
| 52-Week Range | 0.00 - 0.08 |
| Beta | 3.00 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About JSPRW
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$JSPRW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in JSPRW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by JSPRW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
JSPRW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New JSPRW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to JSPRW from public contracts
Source: USAspending.gov
JSPRW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from JSPRW’s recent data — informational, not investment advice